The lesson: A voluntary nationwide recall of Kian Pee Wan capsules — triggered by FDA analysis finding undeclared pharmaceutical drugs in a product marketed as a dietary supplement — is a stark reminder that ingredient control failures don't stay hidden forever. The question is whether your quality system finds them first, or the FDA does.
On March 30, 2026, the FDA announced that Aphreseller (eBay seller ID), operating as Buy-herbal.com out of Flushing, New York, was recalling all lots of Kian Pee Wan capsules to the consumer level. The reason: FDA laboratory analysis confirmed the product contained dexamethasone and cyproheptadine — two potent pharmaceutical drugs — neither of which was disclosed on the label. You can review the official FDA recall notice here.
Dexamethasone is a corticosteroid with serious risks including immunosuppression, adrenal suppression, and dangerous drug interactions. Cyproheptadine is an antihistamine with sedative properties. Consumers purchasing what they believed was a natural herbal supplement were unknowingly ingesting prescription-strength pharmaceutical compounds — with no warning, no dosage guidance, and no opportunity to make an informed decision.
This wasn't a freak laboratory accident. It was a quality system failure — one that is entirely preventable. In this article, I'll walk through exactly what controls, testing protocols, and manufacturing practices would have stopped this recall before it started.
Why Undeclared Drug Ingredients in Supplements Are a Persistent Problem
The dietary supplement industry remains one of the most challenging regulatory environments in FDA compliance. Unlike pharmaceutical manufacturers, dietary supplement companies are not required to obtain premarket approval from the FDA. However, they are absolutely required to comply with 21 CFR Part 111 — Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements.
This regulation is explicit: manufacturers must establish and follow written procedures for every step of their process, conduct identity testing on every ingredient, and ensure that finished products meet established specifications before they are released to market.
The problem? Too many supplement sellers — particularly those operating through third-party online marketplaces like eBay or direct-to-consumer websites — treat these requirements as optional overhead rather than non-negotiable compliance obligations.
The FDA's Dietary Supplement Ingredient Directory and its ongoing Operation Supplement Safety (OPSS) program have identified hundreds of products adulterated with undeclared pharmaceutical ingredients over the past decade. According to FDA data, the most commonly adulterated supplement categories include weight loss, sexual enhancement, bodybuilding, and joint/pain products. Products marketed for appetite stimulation and weight gain — a category Kian Pee Wan capsules appear to target — fall squarely in this high-risk zone.
A critical statistic: The FDA has identified more than 1,000 dietary supplement products adulterated with undeclared active pharmaceutical ingredients since 2007, with enforcement actions accelerating significantly in recent years as analytical testing capabilities have improved.
The Regulatory Framework: What 21 CFR Part 111 Actually Requires
Before discussing what went wrong and how to prevent it, it's important to be precise about what the law requires. Failing to understand these obligations — or dismissing them as "bureaucratic formalities" — is how companies end up in recall situations.
Identity Testing: The Non-Negotiable Foundation (21 CFR § 111.75)
Under 21 CFR § 111.75(a)(1), dietary supplement manufacturers must test 100% of incoming dietary ingredients to verify identity before use. This is not a risk-based sampling requirement — identity testing must be performed on every lot of every ingredient received.
Furthermore, 21 CFR § 111.75(c) requires that finished batches be tested or examined to determine whether they meet product specifications, including identity, purity, strength, and composition.
What this means in practice: If you are sourcing herbal capsules or blended formulations from a third-party supplier — particularly an overseas supplier — you cannot simply rely on a Certificate of Analysis (CoA) from that supplier. You must independently verify identity through your own laboratory testing or a qualified third-party contract laboratory.
Supplier Qualification: Your First Line of Defense (21 CFR § 111.70)
21 CFR § 111.70 requires that manufacturers establish product specifications for each dietary ingredient and dietary supplement they manufacture. This includes specifications that, if not met, would indicate adulteration.
A robust supplier qualification program must include:
- Documented supplier approval processes with defined qualification criteria
- On-site or remote audits of supplier manufacturing facilities
- Review of supplier cGMP compliance records and any prior FDA enforcement history
- Lot-by-lot CoA review against established specifications
- Periodic re-qualification of approved suppliers
The Kian Pee Wan case highlights a supply chain control gap that is especially common among small supplement sellers who source pre-made capsule formulations from overseas manufacturers and then relabel or resell them with minimal — or zero — independent verification.
Finished Product Testing: Your Last Line of Defense
Even with robust incoming ingredient testing and supplier qualification, finished product testing remains a critical control. For products in high-risk categories — particularly those with traditional or ethnic herbal formulations — finished product testing should include targeted screening for pharmaceutical adulterants.
The analytical methods available today make this more feasible than ever:
| Testing Method | What It Detects | Relative Cost | Turnaround |
|---|---|---|---|
| HPLC (High-Performance Liquid Chromatography) | Specific pharmaceutical compounds | Moderate | 3–5 business days |
| LC-MS/MS (Liquid Chromatography–Mass Spectrometry) | Broad pharmaceutical adulterant screening | Moderate–High | 5–10 business days |
| NIR Spectroscopy | Rapid identity screening | Low | Same day |
| ICP-MS (Inductively Coupled Plasma–MS) | Heavy metals | Moderate | 3–5 business days |
| Microbiological Testing | Pathogens, total plate count | Low–Moderate | 5–7 business days |
For products in the appetite stimulation, weight management, or pain relief categories, LC-MS/MS pharmaceutical adulterant screening is no longer optional — it's a practical necessity. The FDA routinely uses this methodology in its own surveillance testing, which is precisely how dexamethasone and cyproheptadine were identified in Kian Pee Wan capsules.
The Four Quality System Failures Behind Most Supplement Adulteration Recalls
In my experience working with 200+ clients across dietary supplement, pharmaceutical, and medical device industries, undeclared ingredient recalls almost always trace back to one or more of these four systemic failures:
1. Absence of a Formal Supplier Qualification Program
This is the most common failure mode. Many small and mid-size supplement companies — particularly those selling through online marketplaces — source products from overseas brokers or wholesale suppliers without any formal qualification process. A CoA from an unqualified supplier is a piece of paper, not a quality guarantee.
Prevention: Establish a written Approved Supplier List (ASL) and require all suppliers to pass a documented qualification process before any ingredient or finished product is accepted. For high-risk suppliers (those providing complex herbal blends or products from regions with historically high adulteration rates), require annual re-qualification audits.
2. Failure to Conduct Independent Identity Testing
Regulatory cGMP requirements are clear: a supplier's CoA does not substitute for your own identity testing. Yet many supplement sellers skip independent testing entirely, especially when buying pre-manufactured finished dosage forms for relabeling.
Prevention: Establish contracts with qualified third-party contract testing laboratories (CTLs) and include pharmaceutical adulterant screening panels for all products in high-risk categories. Budget for testing as a cost of doing business — it is far cheaper than a recall.
3. Inadequate Batch Records and Traceability
When the FDA identifies an adulterated product in the field, the first thing investigators ask for is your batch records. Without complete, accurate, and traceable batch records — documenting who received the ingredient, from whom, when, what testing was performed, and what the results showed — you cannot demonstrate compliance, cannot conduct an effective recall, and cannot defend yourself in an enforcement proceeding.
Prevention: Implement a robust Master Manufacturing Record (MMR) and Batch Production Record (BPR) system. Ensure all records are reviewed and signed off before product release. Records must be retained for one year past the product's shelf life or two years past the date of sale, whichever is longer (21 CFR § 111.605).
4. No Written Recall Procedure
Many companies don't think about their recall procedure until they need it — at which point it is far too late to build one from scratch. Under 21 CFR § 7.59, firms are expected to cooperate with FDA recall requests and maintain adequate distribution records to support effective recall execution.
Prevention: Develop, document, and periodically test a written Recall Procedure. This should include a mock recall exercise at least annually to verify that your traceability systems can identify and account for all affected units within 24–48 hours of a recall decision.
What a Prevention-Ready Quality System Looks Like
The following framework represents the minimum viable quality infrastructure for a dietary supplement company that wants to stay out of an FDA recall notice:
Incoming Material Controls
- Written specifications for every ingredient and raw material
- 100% identity testing on all incoming dietary ingredients (per 21 CFR § 111.75)
- Supplier CoA review against established specifications for every lot
- Quarantine of incoming materials pending release by Quality
In-Process Controls
- Written Master Manufacturing Records with clear critical control points
- In-process checks documented in Batch Production Records
- Environmental monitoring where appropriate
- Calibrated, maintained equipment with documented records
Finished Product Controls
- Finished product specifications covering identity, purity, strength, and composition
- Finished product testing before release — including adulterant screening for high-risk categories
- Formal Product Release process requiring Quality sign-off
- Certificate of Conformance (CoC) retention for every released lot
Post-Market Surveillance
- Written Consumer Complaint procedure
- Adverse Event Reporting system (mandatory for serious adverse events under 21 CFR § 111.570)
- Trend analysis of complaints to detect potential quality signals early
- Annual Product Review (APR) process
Online Marketplace Sellers Face Amplified Regulatory Risk
The Kian Pee Wan recall is notable not just for what was found in the product, but for where the product was being sold: eBay and a direct-to-consumer website. This channel dynamic is important.
The FDA has made clear in recent years that online marketplace sellers are subject to the same cGMP requirements as traditional brick-and-mortar supplement manufacturers. Selling on eBay, Amazon, or Shopify does not reduce your regulatory obligations — it simply changes your customer acquisition channel.
In fact, online sellers often face greater enforcement risk because:
- Their products are easily accessible to FDA investigators without a field inspection
- Consumer complaints flow easily through online review platforms and directly to the FDA's MedWatch system
- Marketplace platforms themselves increasingly require compliance documentation and may report problematic sellers
A direct citation hook: Any person who manufactures, packages, labels, or holds a dietary supplement for sale in the United States is subject to 21 CFR Part 111 — regardless of the sales channel through which the product reaches consumers.
Practical Compliance Steps You Can Take Right Now
If you are a dietary supplement manufacturer, private labeler, or online seller, here is a prioritized action plan based on the lessons from this recall:
Immediate (within 30 days): - [ ] Audit your current supplier list — do you have documented qualification records for every supplier? - [ ] Confirm that identity testing is being performed on 100% of incoming dietary ingredient lots - [ ] Identify any products in high-risk categories (weight loss, appetite stimulation, joint/pain, sexual enhancement, bodybuilding) that have not been screened for pharmaceutical adulterants
Short-Term (within 60–90 days): - [ ] Establish or update your written Supplier Qualification Procedure - [ ] Establish contracts with qualified third-party contract testing laboratories - [ ] Review and update your Batch Production Record templates to ensure full traceability - [ ] Develop or update your written Recall Procedure and schedule a mock recall exercise
Ongoing: - [ ] Conduct annual supplier re-qualification audits for high-risk suppliers - [ ] Review consumer complaints monthly for quality signals - [ ] Perform an Annual Product Review for each SKU in your portfolio - [ ] Stay current with FDA guidance documents and enforcement trends through resources like thefdaexpert.com
The Cost of Getting It Wrong
The financial and reputational consequences of an FDA recall far exceed the cost of a robust quality system. Consider:
- Direct recall costs (notification, retrieval, destruction) can range from tens of thousands to hundreds of thousands of dollars depending on product volume and distribution reach
- Legal liability from consumers harmed by undeclared pharmaceutical ingredients — particularly potent corticosteroids like dexamethasone — can dwarf direct recall costs
- Permanent reputational damage in an era where recall notices are permanently indexed online
- Criminal referral risk for knowing violations of the Federal Food, Drug, and Cosmetic Act
The FDA's enforcement posture on supplement adulteration has intensified. The agency's Dietary Supplement Program has increasingly prioritized import surveillance, online marketplace monitoring, and laboratory testing of products purchased through e-commerce channels. If you are selling supplements online without a compliant quality system, the question is not if the FDA will find a problem — it is when.
A second citation hook: The average cost of a dietary supplement recall, including direct costs, lost revenue, and reputational impact, significantly exceeds the annual cost of implementing a fully compliant 21 CFR Part 111 quality management system.
Working With a Qualified Consultant
Navigating 21 CFR Part 111 compliance is complex, and the stakes — as the Kian Pee Wan recall demonstrates — are very real. At Certify Consulting, I've helped more than 200 clients build dietary supplement quality systems that pass FDA scrutiny the first time. Our clients maintain a 100% first-time audit pass rate because we build compliance into operations from the ground up, not as an afterthought.
Whether you're launching a new supplement brand, bringing your existing operations into compliance, or responding to an FDA inquiry or recall situation, having experienced guidance makes the difference between a controlled outcome and a public enforcement action.
Ready to assess your supplement quality system? Visit certify.consulting to schedule a consultation with Jared Clark and learn how Certify Consulting can protect your brand, your customers, and your business.
For more on FDA enforcement trends in dietary supplements and related compliance topics, explore additional resources at thefdaexpert.com.
Frequently Asked Questions
What regulations apply to dietary supplement manufacturers regarding ingredient testing?
Under 21 CFR Part 111 (Dietary Supplement cGMPs), manufacturers must test 100% of incoming dietary ingredients for identity before use (§ 111.75) and must test or examine finished batches to confirm they meet established specifications for identity, purity, strength, and composition before release.
What are undeclared drug ingredients and why are they dangerous in supplements?
Undeclared drug ingredients are active pharmaceutical compounds present in a product that are not listed on the label. They are dangerous because consumers are unaware they are ingesting them, cannot make informed decisions, may experience serious drug interactions, and receive no dosage guidance. In the Kian Pee Wan recall, these undeclared ingredients were dexamethasone (a potent corticosteroid) and cyproheptadine (an antihistamine with sedative effects).
Do online marketplace sellers like eBay sellers have to comply with FDA supplement cGMPs?
Yes. Any person who manufactures, packages, labels, or holds a dietary supplement for sale in the United States must comply with 21 CFR Part 111, regardless of whether they sell through a physical store, a website, or a third-party online marketplace like eBay or Amazon. Sales channel does not affect regulatory obligation.
What testing methods detect pharmaceutical adulterants in dietary supplements?
The most effective method for broad pharmaceutical adulterant screening is LC-MS/MS (Liquid Chromatography–Mass Spectrometry), which can detect a wide range of drug compounds at low concentrations. HPLC is used for targeted screening of specific known adulterants. The FDA uses these same methods in its own laboratory surveillance program.
What should a supplement company do if it discovers a potential adulteration issue?
Immediately quarantine all affected lots and prevent further distribution. Conduct a thorough investigation to determine the root cause and scope. Contact an experienced FDA regulatory consultant. If a recall is warranted, notify the FDA and follow the procedures outlined in 21 CFR Part 7. Document all actions taken throughout the process.
Last updated: 2026-04-10
Jared Clark is Principal Consultant at Certify Consulting and a recognized expert in FDA regulatory compliance for dietary supplements, pharmaceuticals, and medical devices. With 8+ years of experience and a 100% first-time audit pass rate across 200+ clients, Jared helps companies build quality systems that protect patients and prevent enforcement actions. Learn more at certify.consulting.
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.